Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

Venous thromboembolic disease (VTD) is a recently recognized complication of thalidomide in combination therapy for patients with multiple myeloma (MM). The authors assessed the frequency of VTD and its risk factors in 612 consecutive patients with plasma cell dyscrasia (PCD) who were evaluated and followed from 1991 to 2001.

[1]  H. Kaufmann,et al.  Advances in the biology and therapeutic management of multiple myeloma , 2001, Annals of Hematology.

[2]  J. Crowley,et al.  A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience , 2003, British journal of haematology.

[3]  F. Anderson,et al.  Physician practices in the management of venous thromboembolism: a community-wide survey. , 1992, Journal of vascular surgery.

[4]  Z. Ahmed,et al.  Deep Vein Thrombosis as a Predictor of Cancer , 1996, Angiology.

[5]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[6]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[7]  S. Ward,et al.  Thromboembolism in Patients on Thalidomide for Myeloma , 2002, Hematology.

[8]  R. Kurzrock,et al.  Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. , 1997, The American journal of medicine.

[9]  D. Gabriel,et al.  The influence of immunoglobulin (IgG) on the assembly of fibrin gels. , 1983, The Journal of laboratory and clinical medicine.

[10]  J. Pearson,et al.  Abnormal Fibrin Ultrastructure, Polymerization, and Clot Retraction in Multiple Myeloma * , 1970, British journal of haematology.

[11]  J. Hogg,et al.  Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. , 2000, American journal of physiology. Heart and circulatory physiology.

[12]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.

[13]  T. Choueiri,et al.  Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. , 2003, British journal of haematology.

[14]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[15]  B. Brenner,et al.  Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. , 2001, The American journal of medicine.

[16]  Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders. , 2002, Haematologica.

[17]  G. Srkalović,et al.  Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma , 2002, Medical oncology.

[18]  M. Baccarani,et al.  Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. , 2002, Blood.

[19]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[20]  B. Barlogie,et al.  Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  R. Nachman,et al.  Inhibition of fibrin monomer polymerization by lambda myeloma globulins. , 1972, Blood.

[22]  B. Barlogie,et al.  Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. , 2002, Blood.

[23]  E. Keller,et al.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. , 2000, Annual review of medicine.

[24]  R J Hettiarachchi,et al.  Undiagnosed malignancy in patients with deep vein thrombosis , 1998, Cancer.

[25]  R. Kriz,et al.  Stimulation of murine hemopoietic colony formation by human IL-6. , 1988, Journal of immunology.

[26]  Hannes Kaufmann,et al.  Thromboembolic events during treatment with thalidomide. , 2002, Blood.

[27]  M. Prins,et al.  Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. , 1992, The New England journal of medicine.

[28]  M. Carr,et al.  Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. , 1996, The Journal of laboratory and clinical medicine.

[29]  S. Rajkumar,et al.  Deep venous thrombosis and thalidomide therapy for multiple myeloma. , 2001, The New England journal of medicine.